Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Clin Med ; 11(7)2022 Apr 04.
Artículo en Inglés | MEDLINE | ID: mdl-35407623

RESUMEN

Background: Cinacalcet is a calcimimetic drug that has increasingly been used as a bridging therapy for primary hyperparathyroidism (pHPT), especially during the COVID-19 pandemic. The aim of our study was to investigate if preoperative cinacalcet therapy affects intraoperative parathyroid hormone (IOPTH) monitoring during parathyroidectomy, which is an important indicator for the success of surgery. Methods: In this single-center retrospective analysis, we studied the outcomes of 72 patients who underwent surgery for pHPT. We evaluated two groups: those with cinacalcet therapy before operation­the cinacalcet group (CG)­and those without medical therapy preoperatively (non-CG). In order to perform a between-group comparison of time trends, we fit a linear mixed-effects model with PTH as the response variable and predictors PTH levels preoperatively, group (cinacalcet yes/no), time, the group-by-time interaction, and a random intercept (per subject). Results: Our cohort included 51 (71%) women and 21 (29%) men, who were operated upon for pHPT in the period from January 2018 until August 2021. All patients were diagnosed with pHPT and 54% of the cohort were symptomatic for hypercalcemia. Moreover, 30% of the patients were treated with cinacalcet as a bridging therapy preoperatively, and this increased during the COVID-19 pandemic, as 64% of this group were treated in the last two years. Calcium values were significantly different before (p < 0.001) and after (p = 0.0089) surgery, but calcium level change did not differ significantly between the CG and non-CG. Parathyroid hormone (PTH) levels dropped significantly in both groups during 10 min IOPTH monitoring (p < 0.001), but there was no significant difference between the two groups (p = 0.212). Conclusions: In the examined patient cohort, the use of cinacalcet did not affect the value of IOPTH monitoring during surgery for pHPT.

2.
Bioorg Med Chem Lett ; 24(1): 280-2, 2014 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-24314669

RESUMEN

A high-throughput molecular docking approach was successfully applied for the selection of potential inhibitors of the Influenza RNA-polymerase which act by targeting the PA-PB1 protein-protein interaction. Commercially available compounds were purchased and biologically evaluated in vitro using an ELISA-based assay. As a result, some compounds possessing a 3-cyano-4,6-diphenyl-pyridine nucleus emerged as effective inhibitors with the best ones showing IC50 values in the micromolar range.


Asunto(s)
Inhibidores Enzimáticos/farmacología , Virus de la Influenza A/enzimología , Piridinas/farmacología , ARN Polimerasa Dependiente del ARN/antagonistas & inhibidores , Proteínas Virales/antagonistas & inhibidores , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/química , Ensayos Analíticos de Alto Rendimiento , Modelos Moleculares , Estructura Molecular , Unión Proteica/efectos de los fármacos , Piridinas/química , ARN Polimerasa Dependiente del ARN/metabolismo , Relación Estructura-Actividad , Proteínas Virales/metabolismo
3.
ChemMedChem ; 9(1): 129-50, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24285596

RESUMEN

The influenza RNA polymerase complex, which consists of the three subunits PA, PB1, and PB2, is a promising target for the development of new antiviral drugs. A large library of benzofurazan compounds was synthesized and assayed against influenza virus A/WSN/33 (H1N1). Most of the new derivatives were found to act by inhibiting the viral RNA polymerase complex through disruption of the complex formed between subunits PA and PB1. Docking studies were also performed to elucidate the binding mode of benzofurazans within the PB1 binding site in PA and to identify amino acids involved in their mechanism of action. The predicted binding pose is fully consistent with the biological data and lays the foundation for the rational development of more effective PA-PB1 inhibitors.


Asunto(s)
Antivirales/síntesis química , Benzoxazoles/química , ARN Polimerasas Dirigidas por ADN/antagonistas & inhibidores , Inhibidores Enzimáticos/síntesis química , Subtipo H1N1 del Virus de la Influenza A/enzimología , Proteínas Virales/antagonistas & inhibidores , Antivirales/farmacología , Benzoxazoles/farmacología , Sitios de Unión , ARN Polimerasas Dirigidas por ADN/metabolismo , Inhibidores Enzimáticos/farmacología , Células HEK293 , Humanos , Simulación de Dinámica Molecular , Unión Proteica , Mapas de Interacción de Proteínas/efectos de los fármacos , Estructura Terciaria de Proteína , Subunidades de Proteína/antagonistas & inhibidores , Subunidades de Proteína/metabolismo , Proteínas Virales/metabolismo , Replicación Viral/efectos de los fármacos
4.
Bioorg Med Chem Lett ; 23(20): 5575-7, 2013 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-24012120

RESUMEN

The identification of a novel hit compound inhibitor of the protein-protein interaction between the influenza RNA-polymerase PA and PB1 subunits has been accomplished by means of high-throughput screening. A small family of structurally related molecules has been synthesized and biologically evaluated with most of the compounds showing micromolar potency of inhibition against viral replication.


Asunto(s)
Antivirales/toxicidad , Benzoxazoles/química , ARN Polimerasas Dirigidas por ADN/metabolismo , Inhibidores Enzimáticos/síntesis química , Virus de la Influenza A/efectos de los fármacos , Animales , Antivirales/síntesis química , Antivirales/química , Benzoxazoles/síntesis química , Benzoxazoles/toxicidad , ARN Polimerasas Dirigidas por ADN/química , Perros , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/toxicidad , Virus de la Influenza A/enzimología , Células de Riñón Canino Madin Darby , Dominios y Motivos de Interacción de Proteínas/efectos de los fármacos , Subunidades de Proteína/química , Subunidades de Proteína/metabolismo , Relación Estructura-Actividad
5.
Antimicrob Agents Chemother ; 55(2): 696-702, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21135188

RESUMEN

The influenza A virus polymerase complex, consisting of the subunits PB1, PB2, and PA, represents a promising target for the development of new antiviral drugs. We have previously demonstrated the feasibility of targeting the protein-protein interaction domain between PA and PB1 using peptides derived from the extreme N terminus of PB1 (amino acids [aa] 1 to 15), comprising the PA-binding domain of PB1. To increase the binding affinity of these peptides, we performed a systematic structure-affinity relationship analysis. Alanine and aspartic acid scans revealed that almost all amino acids in the core binding region (aa 5 to 11) are indispensable for PA binding. Using a library of immobilized peptides representing all possible single amino acid substitutions, we were able to identify amino acid positions outside the core PA-binding region (aa 1, 3, 12, 14, and 15) that are variable and can be replaced by affinity-enhancing residues. Surface plasmon resonance binding studies revealed that combination of several affinity-enhancing mutations led to an additive effect. Thus, the feasibility to enhance the PA-binding affinity presents an intriguing possibility to increase antiviral activity of the PB1-derived peptide and one step forward in the development of an antiviral drug against influenza A viruses.


Asunto(s)
Virus de la Influenza A/enzimología , Péptidos/química , Péptidos/metabolismo , ARN Polimerasa Dependiente del ARN/metabolismo , Proteínas Virales/química , Proteínas Virales/metabolismo , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Línea Celular , Humanos , Virus de la Influenza A/metabolismo , Datos de Secuencia Molecular , Péptidos/síntesis química , Unión Proteica , Dominios y Motivos de Interacción de Proteínas , Relación Estructura-Actividad , Proteínas Virales/genética
6.
PLoS One ; 4(10): e7517, 2009 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-19841738

RESUMEN

There is an urgent need for new drugs against influenza type A and B viruses due to incomplete protection by vaccines and the emergence of resistance to current antivirals. The influenza virus polymerase complex, consisting of the PB1, PB2 and PA subunits, represents a promising target for the development of new drugs. We have previously demonstrated the feasibility of targeting the protein-protein interaction domain between the PB1 and PA subunits of the polymerase complex of influenza A virus using a small peptide derived from the PA-binding domain of PB1. However, this influenza A virus-derived peptide did not affect influenza B virus polymerase activity. Here we report that the PA-binding domain of the polymerase subunit PB1 of influenza A and B viruses is highly conserved and that mutual amino acid exchange shows that they cannot be functionally exchanged with each other. Based on phylogenetic analysis and a novel biochemical ELISA-based screening approach, we were able to identify an influenza A-derived peptide with a single influenza B-specific amino acid substitution which efficiently binds to PA of both virus types. This dual-binding peptide blocked the viral polymerase activity and growth of both virus types. Our findings provide proof of principle that protein-protein interaction inhibitors can be generated against influenza A and B viruses. Furthermore, this dual-binding peptide, combined with our novel screening method, is a promising platform to identify new antiviral lead compounds.


Asunto(s)
ARN Polimerasas Dirigidas por ADN/química , Virus de la Influenza A/metabolismo , Virus de la Influenza B/metabolismo , Replicación Viral , Secuencia de Aminoácidos , Animales , Antivirales/química , Antivirales/farmacología , Línea Celular , Química Farmacéutica/métodos , Perros , Diseño de Fármacos , Humanos , Datos de Secuencia Molecular , Unión Proteica , Estructura Terciaria de Proteína , ARN Polimerasa Dependiente del ARN/química , Proteínas Recombinantes de Fusión/química , Homología de Secuencia de Aminoácido
7.
Cytokine ; 38(2): 61-73, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17611121

RESUMEN

Interleukin (IL)-15 has critical impact on the homeostasis and activation of natural killer cells, natural killer T cells, gammadeltaT cells, and CD8(+)T cells, and contributes to antimicrobial defenses particularly at mucosal sites. The respiratory tract comprises a large mucosal surface and harbors significant amounts of lymphocytes, however the expression pattern of IL-15 in the lung and its role in local immune responses are largely unknown. We therefore analyzed the differential expression of IL-15 and the IL-15 receptor (IL-15R) complex in the lungs of mice and demonstrated substantial constitutive expression in bronchial and alveolar epithelial cells, alveolar macrophages, and vascular smooth muscle cells, implicating contribution to pulmonary immune cell homeostasis already under normal conditions. The induction of pneumococcal pneumonia but not the infection with Chlamydophila pneumoniae evoked a significant up-regulation of IL-15 on alveolar macrophages and bronchial epithelial cells, with the latter presenting de-novo expression of IL-15 on their basolateral surface and additional up-regulation of IL-15Ralpha. Moreover, transcriptome analysis as well as semi-quantitative PCR indicated at least partial transcriptional regulation in mice lungs. In conclusion IL-15 is suggested being of functional importance in the pulmonary immune response against pneumococcal pneumonia.


Asunto(s)
Infecciones por Chlamydia/metabolismo , Regulación de la Expresión Génica/fisiología , Interleucina-15/genética , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/metabolismo , Receptores de Interleucina-15/genética , Animales , Infecciones por Chlamydia/inmunología , Infecciones por Chlamydia/patología , Femenino , Subunidad gamma Común de Receptores de Interleucina/biosíntesis , Subunidad gamma Común de Receptores de Interleucina/genética , Interleucina-15/biosíntesis , Subunidad alfa del Receptor de Interleucina-15/biosíntesis , Subunidad alfa del Receptor de Interleucina-15/genética , Subunidad beta del Receptor de Interleucina-2/biosíntesis , Subunidad beta del Receptor de Interleucina-2/genética , Pulmón/metabolismo , Pulmón/patología , Ratones , Ratones Endogámicos C57BL , Neumonía Neumocócica/patología , Receptores de Interleucina-15/biosíntesis
8.
Arch Pharm (Weinheim) ; 339(9): 489-97, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16929558

RESUMEN

Advances in modern medicinal chemistry have enabled scientists to engineer new pathways aiming at the generation of novel chemical entities. Random chemistry, the serendipitous synthesis of small-compound libraries by gamma-irradiation of a highly active lead compound or pharmacophoric fragments of active compounds, represents a complementary methodology, which provides both, compounds with resembling molecular structure and rearranged structures not previously known. Since the libraries are likely to be derived from radical chemistry, Fenton's reagent was applied to a methanol/water solution of tacrine to mimic the irradiation. Indeed, the experiment resulted in a similar product spectrum as found for tacrine in water and methanol solutions after (60)Co irradiation. However, the application of Fenton's reagent is limited due to its poor solubility in organic solvents. Since the drugs we are aiming for should exhibit high water solubility, this limitation can be regarded as an advantage at the same time. Further extension of the random chemistry approach led to the successful irradiation of non-active but drugable single fragments and combinations of fragments, i.e. the irradiation of tetrahydroisoquinoline and benzylamine, both being fragments of naphthylisoquinolines with antiplasmodial activity. The obtained isoquinoline derivatives were found to exhibit anti-infective activities and thus are promising new lead structures.


Asunto(s)
Química Farmacéutica/métodos , Técnicas Químicas Combinatorias/métodos , Química Farmacéutica/tendencias , Modelos Teóricos , Estructura Molecular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...